Gilder Gagnon Howe & Co. LLC Takes Position in Natera Inc (NTRA)

Gilder Gagnon Howe & Co. LLC bought a new position in Natera Inc (NASDAQ:NTRA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 43,243 shares of the medical research company’s stock, valued at approximately $1,035,000. Gilder Gagnon Howe & Co. LLC owned approximately 0.07% of Natera at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Jennison Associates LLC lifted its holdings in shares of Natera by 1.4% in the 2nd quarter. Jennison Associates LLC now owns 2,617,623 shares of the medical research company’s stock worth $49,264,000 after purchasing an additional 36,876 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Natera by 19.4% in the 2nd quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock worth $39,274,000 after purchasing an additional 338,766 shares during the last quarter. Fred Alger Management Inc. bought a new stake in shares of Natera in the 2nd quarter worth approximately $33,271,000. Macquarie Group Ltd. lifted its holdings in shares of Natera by 9.0% in the 2nd quarter. Macquarie Group Ltd. now owns 1,714,886 shares of the medical research company’s stock worth $32,274,000 after purchasing an additional 141,278 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Natera by 35.2% in the 2nd quarter. Renaissance Technologies LLC now owns 792,400 shares of the medical research company’s stock worth $14,913,000 after purchasing an additional 206,471 shares during the last quarter. 66.95% of the stock is currently owned by institutional investors and hedge funds.

Shares of Natera stock opened at $22.34 on Friday. Natera Inc has a 1-year low of $8.60 and a 1-year high of $29.62.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, meeting the consensus estimate of ($0.55). The firm had revenue of $63.07 million for the quarter, compared to the consensus estimate of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The firm’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.55) EPS. Research analysts anticipate that Natera Inc will post -2.02 earnings per share for the current year.

NTRA has been the topic of several recent research reports. Piper Jaffray Companies raised their price target on Natera to $27.00 and gave the stock an “overweight” rating in a report on Thursday, August 9th. Canaccord Genuity raised their price target on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 16th. TheStreet raised Natera from a “d” rating to a “c-” rating in a report on Thursday, August 9th. BidaskClub raised Natera from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 17th. Finally, Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Natera has a consensus rating of “Buy” and an average price target of $26.00.

In other Natera news, CFO Michael Burkes Brophy sold 108,108 shares of Natera stock in a transaction on Friday, September 14th. The stock was sold at an average price of $24.31, for a total transaction of $2,628,105.48. Following the sale, the chief financial officer now owns 22,000 shares of the company’s stock, valued at approximately $534,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew Rabinowitz sold 403,462 shares of Natera stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $24.90, for a total value of $10,046,203.80. Following the sale, the chief executive officer now directly owns 1,701,686 shares in the company, valued at approximately $42,371,981.40. The disclosure for this sale can be found here. Insiders have sold a total of 2,014,988 shares of company stock worth $48,674,710 in the last ninety days. 13.18% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: Cash Flow Analysis in Stock Selection

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply